 Home > Medical News > Medicines Company News > Laikai Pharmaceuticals LAE201INT2101 Clinical Phase I/II study completed the first subject administration in Korea

Laikai Pharmaceuticals LAE201INT2101 Clinical Phase I/II study completed the first subject administration in Korea

 Last Update: 2022-09-14
 Source: Internet
 Author: User

Tags

citalopram drug

cipro drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Laikai Pharmaceuticals announced that its PHASE I/II clinical study of LAE201INT2101 completed its first human administration yesterday at Seoul National University Hospital in South Korea

LAE201INT2101 is a multicenter, open-label Phase I/II clinical study evaluating the safety and antitumor efficacy

Drug-resistant advanced prostate cancer is currently one

In addition to Seoul National University Hospital in South Korea, four other clinical centers in Korea have also fully launched trials

"Globalization has been a firm goal

Laikai Pharmaceuticals announced that its PHASE I/II clinical study of LAE201INT2101 completed its first human administration yesterday at Seoul National University Hospital in South Korea

LAE201INT2101 is a multicenter, open-label Phase I/II clinical study evaluating the safety and antitumor efficacy

Drug-resistant advanced prostate cancer is currently one

In addition to Seoul National University Hospital in South Korea, four other clinical centers in Korea have also fully launched trials

"Globalization has been a firm goal

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.